Preclinical evaluation of complement receptor targeted drugs for neurological disease

This Earmarked Scholarship project is aligned with a recently awarded Category 1 research grant. It offers you the opportunity to work with leading researchers and contribute to large projects of national significance.

Supervisor – Professor Trent Woodrufft.woodruff@uq.edu.au

There is now clear evidence that the innate immune complement system is associated with the progression of neurodegenerative diseases such as Alzheimer's disease and motor neuron disease. What is less clear, is the role individual complement components and their receptors play in these diseases. Our laboratory has demonstrated that in contrast to other neuro-pathogenic complement factors such as C5a, the complement factor C3a exerts neuro-protective effects in the brain. We have developed several compounds that utilise this protective activity of C3a. This project will evaluate the preclinical properties of these compounds in pharmacological, pharmacokinietic, toxicological and analytical assays designed to identify lead candidates, and acccelerate progression towards clinical trials.

Preferred educational background

Applications will be judged on a competitive basis taking into account the applicant's previous academic record, publication record, honours and awards, and employment history.

A working knowledge of pharmacology/drug development and neurological disease would be of benefit to someone working on this project.

The applicant will demonstrate academic achievement in the field(s) of biomedical science and the potential for scholastic success.

A background or knowledge of drug development and neuroscience is highly desirable.

*The successful candidate must commence by Research Quarter 4, 2021. You should apply at least 3 months prior to the research quarter commencement date. International applicants may need to apply much earlier for visa reasons.

Apply now